FDA will rule on Sprout Pharmaceuticals' Drug for Female Sexual Dysfuntion

In the coming weeks, the FDA will rule on Sprout Pharmaceuticals’ drug flibanserin, a treatment for female sexual dysfunction. This will be the third time that Sprout Pharmaceuticals will seek approval for the medication.
According to an article on Fierce Biotech:

What has changed to make a “yes” more likely this time? First off, Sprout has completed three new Phase I studies designed to address concerns about flibanserin’s interaction with other drugs and its effect on patients’ ability to drive the morning after use.
A less concrete–but potentially significant–influence this time around, though, has been the voice of a persuasive advocacy group called “Even the Score.” It’s a coalition of women and healthcare groups founded in 2014 after the second rejection of flibanserin.
[…] Even the Score has worked diligently to raise awareness about the issue of female sexual dysfunction, especially the disparity in treatment options compared with the numerous drugs for males. Public relations efforts have included a nationwide petition, which was signed by 55,000 women, and encouraging people to write their Congress members.

Click here to read the full article on Fierce Biotech.